TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2013, Pages

  Zambad, Shitalkumar P ^a   Tuli, Davinder ^a   Mathur, Anoop ^a   Ghalsasi, Sameer A ^a   Chaudhary, Anita R ^a   Deshpande, Shailesh ^a   Gupta, Ramesh C ^a   Chauthaiwale, Vijay ^a   Dutt, Chaitanya ^a  

^a Torrent Pharmaceuticals Ltd   (India)

Author keywords

Atherogenic dyslipidemia; Cardiovascular risks; Diabesity; Remnant cholesterol; TGR5; Triglyceride clearance

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (4 CHLOROPHENYL) 2 (4 FLUOROPHENOXY) N METHYLIMIDAZO (1,2 A) PYRIMIDINE 3 CARBOXAMIDE; SITAGLIPTIN; TRC 210258; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAMSTER; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 84891059119     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S50209     Document Type: Article

References (29)

1. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26:28-35.
2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33:442-449.
3. Tschop MH, DiMarchi RD. Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity. The case for personalized combinatorial therapies. Diabetes. 2012;61:1309-1314.
4. Haslam D. Obesity and diabetes: the links and common approaches. Prim Care Diabetes. 2010;4:105-112.
5. Meigs JB. Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care. 2010;33:1865-1871.
6. Fruchart JC, Sacks FM, Hermans MP. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010;26:1793-1797.
7. Hermans MP, Fruchart JC. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Ther Adv Chronic Dis. 2011;2:307-323.
8. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379-387.
9. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-436.
10. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319-335.
11. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484-489.
12. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714-719.
13. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167-177.
14. Svensson PA, Olsson M, Andersson-Assarsson JC, et al. The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity, weight loss and resting metabolic rate. Biochem Biophys Res Commun. 2013;433:563-566.
15. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14:747-757.
16. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435-9440.
17. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329:386-390.
18. Wu T, Bound MJ, Standfield SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15:474-477.
19. Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008;372:78-84.
20. Ugawa T, Kakuta H, Moritani H, Shikama H. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol. 2002;135:1572-1578.
21. Li G, Liu X, Zhu H, et al. Insulin resistance in insulin-resistant and diabetic hamsters (Mesocricetus auratus) is associated with abnormal hepatic expression of genes involved in lipid and glucose metabolism. Comp Med. 2009;59:449-458.
22. Nabeno-Kaeriyama Y, Fukuchi Y, Hayashi S, Kimura T, Tanaka A, Naito M. Delayed postprandial metabolism of triglyceride-rich lipoproteins in obese young men compared to lean young men. Clin Chim Acta. 2010;411:1694-1699.
23. Pruneta-Deloche V, Sassolas A, Linga-Thie GM, Berthezene F, Ponsin G, Moulin P. Alteration in lipoprotein lipase activity bound to triglyceride-rich lipoproteins in the postprandial state in type 2 diabetes. J Lipid Res. 2004;45:859-865.
24. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1086-1093.
25. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316.
26. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
27. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102-109.
28. Gupta R, Guptha S, Agrawal A, Kaul V, Gaur K, Gupta VP. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipidemias in an urban Indian population. Lipids Health Dis. 2008;7:40.
29. Zoppini G, Negri C, Stoico V, Casati S, Pichiri I, Bonora E. Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism. 2012;61:22-29.